

GenieMD to offer GRAIL's Multi-Cancer Early Detection as part of Preventive and Longevity Care

GenieMD to offer GRAIL's Multi-Cancer Early Detection as part of Preventive and Longevity Care

SAN FRANCISCO, CA, UNITED STATES,
November 7, 2025 /EINPresswire.com/

-- GenieMD today announced it will integrate GRAIL's groundbreaking

Galleri® multi-cancer early detection (MCED) test into GenieMD's personalized [longevity](#) and preventive health programs, empowering clinicians and patients with access to next-generation cancer screening.



"Our goal at GenieMD is to make early detection and prevention accessible and actionable," said Dr. Soheil Saadat, Founder and CEO of GenieMD. "Offering GRAIL's Galleri test allows us to bring one of the most advanced innovations in multi-cancer early detection directly into personalized care plans bridging the gap between cutting-edge science and everyday clinical practice."

GenieMD will offer the Galleri test as part of its comprehensive preventive and longevity solution, which combines genomics, digital health, and AI-driven insights to help individuals take control of their long-term health offered under GenieMD Elora product suite. The integration aligns with GenieMD's mission to extend healthspan through early detection and proactive care, leveraging technology to deliver precision health at scale.

"Cancer can stay hidden in the body, but many cancers leave clues in the blood in the form of DNA released by the cancer cells long before they cause symptoms. The Galleri test is a multi-cancer early detection blood test that screens for cancers before they become symptomatic, including those cancers without recommended screening tests today," said Megan Hall, PhD., Vice President of Medical and Corporate Affairs at GRAIL. "We applaud GenieMD for its commitment to cancer screening and giving patients more control over their health."

The Galleri test requires a prescription and should be used in addition to recommended cancer screenings such as mammography, colonoscopy, prostate-specific antigen (PSA) test or cervical cancer screening. The Galleri test is now available through GenieMD's clinician network.

nationwide. Patients and providers can learn more or request access by visiting www.GenieMD.com/Elora.

□About GenieMD

□GenieMD is a global, award-winning digital health company dedicated to transforming healthcare delivery through telehealth, remote patient monitoring, and longevity programs. Our comprehensive virtual care platform empowers patients and providers worldwide to connect seamlessly, manage chronic conditions, and detect diseases early promoting healthier, longer lives. Trusted by healthcare organizations across continents, GenieMD combines advanced technology, clinical expertise, and a passion for innovation to make quality care accessible anytime, anywhere.

Important Galleri Safety Information

The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those age 50 or older. The test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. The Galleri test is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of the test is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment. Results should be interpreted by a healthcare provider in the context of medical history, clinical signs, and symptoms. A test result of No Cancer Signal Detected does not rule out cancer. A test result of Cancer Signal Detected requires confirmatory diagnostic evaluation by medically established procedures (e.g., imaging) to confirm cancer. If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False positive (a cancer signal detected when cancer is not present) and false negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.

GenieMD PR
GenieMD, Inc.
+1 925-4609191
[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/865109945>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.